Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-09
2011-08-09
Kemmerer, Elizabeth C (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S016800, C514S016900, C514S017100
Reexamination Certificate
active
07994129
ABSTRACT:
Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.
REFERENCES:
patent: 4086196 (1978-04-01), Tregear
patent: 4698328 (1987-10-01), Neer et al.
patent: 4812304 (1989-03-01), Anderson et al.
patent: 4822609 (1989-04-01), Flora
patent: 5118667 (1992-06-01), Adams et al.
patent: 5164368 (1992-11-01), Recker
patent: 5208041 (1993-05-01), Sindrey
patent: 5317010 (1994-05-01), Pang et al.
patent: 5457092 (1995-10-01), Schluter et al.
patent: 5496801 (1996-03-01), Holthuis et al.
patent: 5510370 (1996-04-01), Hock
patent: 5556940 (1996-09-01), Willick et al.
patent: 5578567 (1996-11-01), Cardinaux et al.
patent: 5589452 (1996-12-01), Krstenansky et al.
patent: 5607915 (1997-03-01), Patton
patent: 5616560 (1997-04-01), Geddes et al.
patent: 5723577 (1998-03-01), Dong
patent: 5744444 (1998-04-01), Forssmann et al.
patent: 5747456 (1998-05-01), Chorev et al.
patent: 5783558 (1998-07-01), Duvos et al.
patent: 5807823 (1998-09-01), Krstenansky et al.
patent: 5814607 (1998-09-01), Patton
patent: 5821225 (1998-10-01), Vickery
patent: 5874086 (1999-02-01), Krstenansky et al.
patent: 5955425 (1999-09-01), Morley et al.
patent: 5977070 (1999-11-01), Piazza et al.
patent: 6025467 (2000-02-01), Fukuda et al.
patent: 6080721 (2000-06-01), Patton
patent: 6110892 (2000-08-01), Barbier et al.
patent: 6284730 (2001-09-01), Dietrich et al.
patent: 6316410 (2001-11-01), Barbier et al.
patent: 6436902 (2002-08-01), Backstrom et al.
patent: 6495662 (2002-12-01), Gardella et al.
patent: 6500647 (2002-12-01), Jung et al.
patent: 6526316 (2003-02-01), Iga et al.
patent: 6583114 (2003-06-01), Vickery
patent: 6590081 (2003-07-01), Zhang
patent: 6756480 (2004-06-01), Kostenuik et al.
patent: 6770623 (2004-08-01), Chang et al.
patent: 6849710 (2005-02-01), Arzeno
patent: 6855337 (2005-02-01), Nelson et al.
patent: 6923968 (2005-08-01), Cantor
patent: 6977077 (2005-12-01), Hock et al.
patent: 7015195 (2006-03-01), Stewart
patent: 7018982 (2006-03-01), Dietrich et al.
patent: 2002/0002135 (2002-01-01), Dietrich et al.
patent: 2002/0025929 (2002-02-01), Sato
patent: 2002/0094951 (2002-07-01), Horiuchi et al.
patent: 2002/0132973 (2002-09-01), Condon et al.
patent: 2002/0136779 (2002-09-01), Lehmann
patent: 2003/0087822 (2003-05-01), Cantor
patent: 2003/0171282 (2003-09-01), Patton
patent: 2004/0005668 (2004-01-01), Gautvik et al.
patent: 2004/0023882 (2004-02-01), Peri et al.
patent: 2004/0033950 (2004-02-01), Hock et al.
patent: 2004/0186050 (2004-09-01), Ault et al.
patent: 2004/0209851 (2004-10-01), Nelson et al.
patent: 2004/0242478 (2004-12-01), Azria et al.
patent: 2004/0242489 (2004-12-01), Mitlak
patent: 2005/0009147 (2005-01-01), Bauer et al.
patent: 2005/0032685 (2005-02-01), Noda
patent: 2005/0032698 (2005-02-01), Day et al.
patent: 2005/0037089 (2005-02-01), Jobbins
patent: 2005/0054557 (2005-03-01), Goldberg
patent: 2005/0095236 (2005-05-01), Zahradnik et al.
patent: 2005/0107292 (2005-05-01), Minamitake et al.
patent: 2005/0119183 (2005-06-01), Wells et al.
patent: 2005/0148763 (2005-07-01), Sekimori et al.
patent: 2005/0192227 (2005-09-01), Hock
patent: 2005/0197294 (2005-09-01), Gaich et al.
patent: 2005/0209144 (2005-09-01), Billger et al.
patent: 2005/0215476 (2005-09-01), Mehta et al.
patent: 2005/0255537 (2005-11-01), Hock et al.
patent: 2005/0256045 (2005-11-01), Ameri et al.
patent: 2005/0272660 (2005-12-01), Gardella et al.
patent: 2005/0276843 (2005-12-01), Quay et al.
patent: 2006/0019902 (2006-01-01), Caporale et al.
patent: 2006/0052305 (2006-03-01), Quay et al.
patent: 2006/0058230 (2006-03-01), Chorev et al.
patent: 2006/0069021 (2006-03-01), Costantino et al.
patent: 2006/0089723 (2006-04-01), Murphy
patent: 2006/0094642 (2006-05-01), Gaich et al.
patent: 2006/0127320 (2006-06-01), Costantino et al.
patent: 1712066 (2005-12-01), None
patent: 0341963 (1989-11-01), None
patent: 0490806 (1992-06-01), None
patent: 1417972 (2004-05-01), None
patent: 2666987 (1992-03-01), None
patent: 2006143603 (2006-06-01), None
patent: WO 93/06846 (1993-04-01), None
patent: WO 94/03201 (1994-02-01), None
patent: WO 95/02610 (1995-01-01), None
patent: WO 96/07416 (1996-03-01), None
patent: WO 96/07417 (1996-03-01), None
patent: WO 96/07418 (1996-03-01), None
patent: WO 96/19246 (1996-06-01), None
patent: WO 96/35447 (1996-11-01), None
patent: WO 98/30590 (1998-07-01), None
patent: WO 00/19823 (2000-04-01), None
patent: WO 01/23521 (2001-04-01), None
patent: WO 01/32201 (2001-05-01), None
patent: WO 2004/024758 (2004-03-01), None
patent: WO 2004/060386 (2004-07-01), None
patent: WO 2004/085562 (2004-10-01), None
patent: WO 2005/002549 (2005-01-01), None
patent: WO 2006/006674 (2006-01-01), None
patent: WO 2006/033912 (2006-03-01), None
patent: WO 2007/059470 (2007-05-01), None
Rosol et al., 1995, Gene 160:241-243.
Akamine, T. et al., “Prostaglandin E2 prevents bone loss and adds extra bone to immobilized distal femoral metaphysis in femal rats,” Bone (1992) 13:11-22.
Altschul, S.F. et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nuc. Acids Res. (1997) 25:3389-3402.
Arnaud, S.B. et al., “Effects of 1-week head-down tilt bed rest on bone formation and the calcium endocrine system,” Aviat. Space Environ. Med. (1992) 63:14-20.
Bakker, A.D. et al., “Interactive effects of PTH and mechanical stress on nitric oxide and PGE2 production by primary mouse osteoblastic cells,” Am. J. Physiol. Endocrinol. Metab. (2003) 285:E608-E613.
Bellido, T. et al., “Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis,” Endocrinology (2005) 146:4577-4583.
Bellido, T. et al., “Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts,” J. Biol. Chem. (2003) 278(50):50259-50272.
Berg, C. et al., “Teriparatide,” Nature Reviews Drug Discovery (2003) 2:257-258.
Bikle, D.D. et al, “The impact of skeletal unloading on bone formation,” Gravit Space Biol. Bull. (2003) 16:45-54.
Bikle, D.D. et al., “Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone,” J. Bone Miner. Res. (2002) 17:1570-1578.
Bikle, D.D. et al., “Skeletal unloading induces resistance to insulin-like growth factor I,” J. Bone Min. Res. (1994) 9:1789-1796.
Bringhurst, F.R. et al., “Peripheral metabolism of PTH: fate of biologically active amino terminus in vivo,” Am. J. Physio. (1988) 255:E886-E893.
Burge, R.T. et al., “Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025,” Value in Health (2003) 6:574-583.
Burguera, B. et al., “Leptin reduces ovariectomy-induced bone loss in rats,” Endocrinology (2001) 142:3546-3553.
Canalis, E. et al., “Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures,” J. Clin. Invest. (1989) 83:60-65.
Carmeliet, G. et al., “Gene expression related to the differentiation of osteoblastic cells is altered by microgravity,” Bone (1998) 22:139S-143S.
Carter, P.H. et al., “The hydrophobic residues phenylalanine 184 and leucine 187 in the type-I parat
Kemmerer Elizabeth C
Michael & Best & Friedrich LLP
Michigan Technological University
LandOfFree
Methods of using black bear parathyroid hormone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using black bear parathyroid hormone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using black bear parathyroid hormone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2736918